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Aim. In the present study, we investigated the protective eﬀect of genistein in experimental acute liver damage induced by CCl 4.
Method. Forty rats were equally allocated to 5 groups. The ﬁrst group was designated as the control group (group 1). The second
group was injected with intraperitoneal CCl 4 for 3 days (group 2). The third group was injected with subcutaneous 1mg/kg
genistein for 4 days starting one day before CCl 4 injection. The fourth group was injected with intraperitoneal CCl 4 for 7 days.
The ﬁfth group was injected with subcutaneous 1mg/kg genistein for 8 days starting one day before CCl 4 injection. Plasma and
liver tissue malondialdehyde (MDA) and liver glutathione levels, as well as AST and ALT levels were studied. A histopathological
examination was conducted. Results. Liver tissue MDA levels were found signiﬁcantly lower in group 3, in comparison to group
2( P<. 05). Liver tissue MDA level in group 5 was signiﬁcantly lower than that in group 4 (P<. 001). Liver tissue glutathione
levels were higher in group 5 and 3, relative to groups 4 and 2, respectively (P>. 05 for each). Inﬂammation and focal necrosis
d e c r e a s e di ng r o u p3 ,i nc o m p a r i s o nt og r o u p2( P<. 001 for each). Inﬂammation and focal necrosis in group 5 was lower than
that in group 4 (P<. 001). Actin expression decreased signiﬁcantly in group 5, relative to group 4 (P<. 05). Conclusion. Genistein
has anti-inﬂammatory and antinecrotic eﬀects on experimental liver damage caused by CCl 4. Genistein reduces liver damage by
preventing lipid peroxidation and strengthening antioxidant systems.
Copyright © 2007 Nalan Kuzu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Phytoestrogens are diphenolic molecules of plant origin,
and resemble estradiol in structure and function. The ma-
jor members of the phytoestrogen family are isoﬂavones, lig-
nans, and coumestans. Of these, isoﬂavones are the most
common and mostly studied phytoestrogens [1, 2]. Some
epidemiologicalstudiesfoundphytoestrogenschemopreven-
tive in cancer and coronary heart disease [3, 4].
Genistein is an isoﬂavone found primarily in the soy pro-
tein [5]. It has an estrogenic and antioxidant activity [6]. It
was argued in previous studies that the beneﬁcial eﬀects of
genistein were associated with its antioxidant eﬀect [7, 8].
Administration of oral genistein was established to reduce
lipid peroxidation in the liver and to increase total antiox-
idant capacity in hamsters [9]. Furthermore, genistein was
found to inhibit tyrosine kinase, which accelerates tumor
growth, and topoisomerase 1 and 2, and to prevent the for-
mation of new capillaries, which is necessary for the growth
of the tumor [1].
Carbon tetrachloride (CCl4)i sat o x i ca g e n tu s e di n
experimental liver damage. It is metabolized by the mito-
chondrial monooxygenase (P450 2E1) system. During the
metabolism, an unstable trichloromethyl (CCl3) free radical
is formed, and rapidly converted to trichloromethyl peroxide
(Cl3COO−)[ 10, 11] .T h e s ef r e er a d i c a l sl e a dt ot h ep e r o x i -
dation of fatty acids found in the phospholipids making up
the cell membranes. Lipid peroxide radicals, lipid hydroper-
oxides, and lipid breakdown products develop in this pro-
cess, and each constitutes an active oxidizing agent. Conse-
quently,cellmembranestructuresandintracellularorganelle
membrane structures are completely broken down. Struc-
tural damage spreads. Chronic administration results in ﬁ-
brosis and cirrhosis [12]. Lipid peroxidation is important in
liver damage associated with CCl4 [13, 14].2 Mediators of Inﬂammation
There are a limited number of studies about the pro-
tective eﬀects of genistein on liver damage. In the present
study,weaimedtoexploretheprotectiveroleoftwodiﬀerent
administration periods of genistein, which has antioxidant
characteristics, in acute liver damage caused by CCl4.
2. MATERIAL AND METHOD
2.1. Experimentalanimals
The study included a total of 40 female Sprague-Dawley rats,
weighing 200 to 260g. The rats were equally allocated to 5
groups. They were kept in specially prepared cages in a room
that had daylight for 12 hours. The study was carried out
in accordance with ethical rules for standard experimental
animal studies. The rats were fed with special rat feed sup-
plied by Elazı˘ g Feed Factory.Water wasgiven through special
dropper-tipped bottles placed specially in the cages.
2.2. Treatmentregimen
Experimental design was shown in Figure 1. One of the ﬁve
groups of rats was designated as the control group (group 1).
The ﬁrst group was injected with subcutaneous olive oil
only. The second group was injected with intraperitoneal
0.15ML/100g CCl4 m i x e dw i t hp u r eo l i v eo i la tar a t eo f
1/2, for 3 days (group 2). The third group was injected
with subcutaneous 1mg/kg genistein (Bonestein, Switzer-
land) for 4 days starting a day before CCl4 injection. CCl4
injection was continued for 3 days in the concerned group
(group 3). The fourth group was injected with intraperi-
toneal 0.15ML/100g CCl4 m i x e dw i t hp u r eo l i v eo i la tar a t e
of 1/2 for 7 days (group 4). The ﬁfth group was injected with
subcutaneous1mg/kg genistein in 0.2ML serumphysiologic
for 8 days starting a day before CCl4 injection. CCl4 injection
was continued for 7 days in the concerned group (group 5).
Rats in groups 2 and 3 were decapitated on the ﬁfth day, 24
hours after the treatment ended. Rats in groups 1, 4, and 5
were decapitated on the ninth day, 24 hours after the treat-
ment was completed. Liver tissue and blood samples were
collected for analysis, and stored at −20◦C.
Preparationofgenistein
Genistein was prepared by dissolving in 100 microliter
DMSO (1.25%) and in the preparation of genistein (in the
PGE) (98.75%) mixture and kept at +8◦C[ 15].
Liver samples were collected from the rats for biochem-
ical and histopathological examination. Tissue samples were
collected accordingly for histopathological examination and
tissue MDA and glutathione levels.
2.3. PlasmaandtissueMDAmeasurements
Plasma MDA levels were determined according to thiobar-
bituric acid method modiﬁed by Yagi [16]. Results were ex-
pressed as nmol/ML. Liver tissue MDA levels were measured
by Ohkawa method. Results were presented as nmol/g tissue
[17].
Experimental design
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Figure 1: Schematic design of study.
2.4. Glutathionelevel
Determination of GSH was carried out as described by Sed-
lak and Lindsay [18]. Results were expressed as μmol/mg
tissue.
2.5. Biochemicalparameters
The blood collected from the rats was centrifuged to sepa-
rate plasma, which was kept at −20◦C until analysis. Alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
alkalenephosphatase(ALP),gammaglutamyltranspeptidase
(γ-GT), urea, and kreatinin levels were measured with olym-
pus kit (Olympus co; Japan) in Olympus AU 600 autoana-
lyzer.
2.6. Histopathologicalexamination
Liver tissue samples were stored in 10% formalin solution to
prepare paraﬃn blocks. Cross sections taken from the blocks
were stained with hematoxylin eosin and masson trichrom.
Histopathological examination was performed by a patholo-
gist who specialized in this ﬁeld. Percentage of steatotic cells
was determined: grading was made as + up to 25%; ++ be-
tween 26 and 50%; +++ between 51 and 75%; ++++ >76%.
Inﬂammatory cells were counted in randomly chosen 10 ar-
eas in x400 magniﬁcation, and mean cells by mm2 were de-
termined by dividing the total by ten [19]. Necrosis foci were
counted in randomly chosen 10 areas in x400 magniﬁcation,
a n dm e a nn e c r o t i cf o c ib ym m 2 were established by dividing
the total by ten [19, 20].
Cross-sections obtained from the paraﬃn blocks were
stained with Masson Trichrom, and examined under x40,
x100, x200, and x400 magniﬁcation. Fibrosis was staged be-
tween 0 and 4: no ﬁbrosis: 0; ﬁbrous portal extension: 1;
bridging ﬁbrosis: 3, cirrhosis: 4.
2.7. Immunohistochemicalstaining
In order to show hepatic stellate cell (HSC) activation, the
liver tissue was stained immunohistochemically by α-SMA
(actinsmoothmuscleneomakers,catalogueno.RB-910-R7).
PresenceofHSCreactiveα-SMAintheliverwasscoredsemi-
quantitatively [21]: grade 0: no or very rare staining; grade
1: staining of stellate cells in <30% of sinusoidal liver cells;Nalan Kuzu et al. 3
Table 1: Level of malondialdehyde (MDA) and gluathione, ALT, AST in groups.
Parameters Control
(group1; n = 8)
CCl 4 3d a y s( g r o u p
2; n = 8)
CCl 4 +genistein
(group 3; n = 8)
CCl 4 7d a y s
(group 4; n = 8)
CCl 4 + genistein
(group 5; n = 7)
ALT (IU/L) 103.85 ±55.58 723.62 ±301.00 361.50 ±39.89(a) 454.14 ±56.66 379.14 ± 42.94(b)
AST (IU/L) 239.14 ±82.05 867.00 ±290.26 660.37 ±84.87(b) 726.28 ±137.40 561.00 ±59.21
Plasma MDA
(nmol/ML) 2.50 ±0.54 4.14 ±1,11 3.20 ±0.66 5.51 ±0.71 3.4 ±0.50(c)
Liver tissue MDA
nmol/gr tissue 19.05 ±1.43 27.02 ±2.54 23.17 ±2.82(d) 33.78 ±2.04 27.20 ±1.68(c)
Liver tissue gluthatione
μmol/mg tissue 10.48 ±0.42 8.72 ±1.30 10.45 ±1.31(e) 7.97 ±1.41 9.83 ±0.88(e)
ALT: Alanine aminotrasferase, AST: Aspartate aminotransferase, MDA: Malondialdehyde.
(a) P<. 001; signiﬁcantly lower in group 3 (CCl4 +genistein) than in group 2 (CCl4)
(b) P<. 05; signiﬁcantly lower in group 3 (CCl4 +genistein) than in group 2 (CCl4) and in group 5 (CCl4 +genistein) than in group 4 (CCl4).
(c) P<. 001; signiﬁcantly lower in group 5 (CCl4 +genistein) than in group 4 (CCl4).
(d) P<. 001; signiﬁcantly lower in group 3 (CCl4 +genistein) than in group 2 (CCl4).
(e) P<. 05: signiﬁcantly increased in group 3 (CCl4 +genistein) than in group 2 (CCl4);i ng r o u p5( CCl4 +genistein) in than group 4 (CCl4).
Table 2: Results of histopathological ﬁndings.
Findings Control (group
1; n = 8)
CCl 4 3d a y s( g r o u p
2; n = 8)
CCl 4 + genistein
(group 3; n = 8)
CCl 4 7d a y s( g r o u p
4; n = 8)
CCl 4 + genistein
(group 5; n = 7)
Steatosis (0–4) — 1.13 + 0,6 1.38 ±0.53 .00 ±0.02 .57 ±0.5
Inﬂammation
(cells/mm2) 1 ±0.77 20.1 ±3.91 2 .8 ±3.6(a) 19.29 ±4.16 .86 ±2.4(a)
Necrosis (foci/mm2)— 1 .10. ±0.20 .7 ±0.2(a) 1.87 ±0.10 .77 ±0.2(a)
Fibrosis (0–4) — 0.63 ±0.60 .88 ±0.42 .14 ±0.91 .57 ±0.9
Actin (α-SMA) expression — 1.38 ±0.51 .87 ±0.22 .86 ±0.42 .00 ±0.5(b)
(a) P<. 001; signiﬁcantly lower in group 3 (CCl4 +genistein) than in group 2 (CCl4) and in group 5 (CCl4 +genistein) than in group 4 (CCl4).
(b) P<. 05; signiﬁcantly lower in group 5 (CCl4 +genistein) than in group 4 (CCl4).
grade 2: staining between 31 and 60%; grade 3: staining be-
tween 61 and 90%; grade 4: diﬀuse staining in more than
90% of sinusoidal liver cells.
2.8. Statisticalevaluation
Data obtained from the study were presented as mean ±
standard deviation. Kruskal Wallis one-way variance analysis
was used in the comparison of parameters between groups,
and Mann Whitney U test was employed in dual evaluations.
SPSS 11.0 package software was used in the statistical evalu-
ation. Level of statistical signiﬁcance was set at P<. 05.
3. RESULTS
One rat in group 5 died in the course of the study. Mean of
the baseline body weight of the rats was comparable between
the groups (P>. 05).
3.1. Biochemicalresults
ALT and AST levels signiﬁcantly increased in all groups, rel-
ative to the control group. ALT and AST levels were found
higheringroup2,relativetogroup1(P<. 001foreach),and
signiﬁcantly lower in group 3, relative to group 2 (P<. 001,
P<. 05, resp.). ALT and AST levels in group 5 were lower
than those in group 4 (P<. 05 for each).
3.2. Lipidperoxidationandglutathionelevels
Plasma MDA and liver tissue MDA levels in groups 2, 3, 4,
and 5 increased relative to the levels in the control group.
Liver glutathione levels in groups 2 and 4 decreased signiﬁ-
cantly in comparison to the control group. Liver tissue MDA
l e v e li ng r o u p3( 2 3 .17 ± 2.82nmol/g tissue) was signiﬁ-
cantlylowerthanthatin group2(27.02±2.54nmol/g tissue)
(P<. 05). Plasma MDA level in group 3 was lower than that
in group 3, but the diﬀerence was not signiﬁcant (P>. 05).
Liver glutathione level was higher in group 3 (10.45 ± 1.3),
relative to group 2 (8.72 ±1.30) (P<. 05).
Liver tissue MDA level in group 5 (33.78 ± 2.04nmol/gr
tissue) was signiﬁcantly lower than that in group 4 (23.17 ±
2.82nmol/gr tissue) (P<. 001). Plasma MDA level was sig-
niﬁcantly lower in group 5 (3.41 ± 0.50nmol/ML), in com-
p a r i s o nt og r o u p4( 4 .14 ± 1.11nmol/ML) (P<. 001). Liver
glutathione levels in group 5 (9.83 ± 0.88) were signiﬁcantly
higher than those in group 4 (7.97 ±1.41) (P<. 05).
Serum ALT, AST, plasma MDA, liver tissue MDA, and
glutathione levels are presented in Table 1.4 Mediators of Inﬂammation
(a)
(b)
(c)
Figure 2: (a) Control (group 1): normal liver histology (H&E
x200); (b) group 4: inﬂammation, necrosis was increased in group
4( C C l 4) (H&E x200); (c) group 5: inﬂammation and necrosis was
decreased in group 5 (CCl4 +genistein): (H&E x200).
3.3. Histopathologicalresults
Steatosis, inﬂammation and necrosis signiﬁcantly increased
in groups 2, 3, 4, and 5, relative to group 1 (P<. 001 for
each). Fibrosis and actin expression in groups 4 and 5 were
higher than that in group 1 (P<. 001). Inﬂammation and
focal necrosis declined in group 3, in comparison to group 2
(P<. 001 for each). There was not any signiﬁcant diﬀerence
between groups 2 and 3 in terms of steatosis, ﬁbrosis, and
actin expression (P>. 05).
Inﬂammation and focal necrosis was found lower in
group 5, relative to group 4 (P<. 001). Actin expression in
group 5 was less than that in group 4 (P<. 05), but there
was no signiﬁcant diﬀerence between the groups in terms of
ﬁbrosis (P>. 05).
There was not any signiﬁcant diﬀerence between groups
with regard to steatosis (P>. 05). Histopathological ﬁndings
are presented in Table 2 and Figures 2 and 3.
(a)
(b)
Figure 3: (a) Group 4: actine expression was increased in group
4 (x400); (b) group5: actine expression was decreased in group 5
(x400).
4. DISCUSSION
Biotransformationofgenisteinmainlyoccursintheliverand
intestines. It is metabolized by cytochrome P450 system. It
is converted into its monohydroxyl and dihydroxyl metabo-
lites(7).Genisteinhasbeeninthespotlightofrecentresearch
since its discovery in 1987. There have been no side eﬀects or
toxicity reported with high doses of genistein in vivo [21].
In this study, administration of genistein for 3 and 7 days
together with CCl4 brought about a signiﬁcant decrease in
liver tissue MDA levels. We also found a signiﬁcant increase
in glutathione levels.
In a recent study, genistein was compared with daidzein
in liver damage induced by CCl4. In a study by Aneja et al.
[22], genistein was administered orally, and CCl4 was in-
jected on the forth and ﬁfth days of the study. In our study,
CCl4 was injected via intraperitoneal route on a daily ba-
sis for 3 and 7 days. Aneja et al. [22] did not perform a
histopathological examination. They found that genistein el-
evated liver tissue glutathione levels, and reduced tissue lipid
peroxidation levels.
Carbon tetrachloride is used to induce experimental liver
damage. The toxic eﬀect of CCl4 is due to the peroxidation
of the membrane lipids by trichloromethyl (CCl31/2 or
CCl3OO1/2) radicals [11, 12]. These radicals initiate lipid
peroxidation chain reactions that start with taking hydrogen
ions from polyunsaturated fatty acids (PUFA). Peroxidation
oflipidscontainingpolyunsaturatedfattyacids,inparticular,
impairs the structure of biological membranes, causing se-
verecelldamage.Thishasasigniﬁcantroleinthepathogene-
sisofmanydiseases[23].Fangetal.[9]showedintheirstudyNalan Kuzu et al. 5
that addition of 50 and 200mg/kg genistein to the diet of
hamsters with vitamin E deﬁciency inhibited oxidative stress
inthelivertissue.Lipidperoxidationinducedbydietaryvita-
min E deﬁciency was reduced by genistein administration. It
was demonstrated that isoﬂavones elevated the cellular glu-
tathione level in biological systems [24, 25]. Genistein can be
eﬀective in the detoxiﬁcation of the toxic metabolites of CCl4
by restoring glutathione levels.
In this study, we established that genistein reduced in-
ﬂammation and necrosis in both groups 3 and 5, relative to
the groups injected with CCl4 only. This eﬀect of genistein
is probably associated with its inhibiting lipid peroxidation
and preventing liver damage. However, it was also claimed
thatthisanti-inﬂammatoryeﬀectwasindependentofthean-
tioxidant eﬀect. Anti-inﬂammatory eﬀects of genistein were
demonstrated in the study by Guo et al. [26] too. Genis-
tein was shown to inhibit NO production from macrophages
stimulated by LPS and IFN γ. In our study, levels of ALT and
AST, which were the markers of liver necrosis and inﬂamma-
tory activity, decreased by genistein administration.
Hepatic stellate cells (HSC) have an important role in
liver ﬁbrosis [27, 28]. Genistein brought about a signiﬁcant
decline in actin expression in group 5 only. HSC can be
activated by many factors like cytokines, lipid peroxidation
products, and so forth [27, 28]. Tyrosine kinase, one of the
factors of HSC activation, has an important role in the pro-
liferation and activation of HSC. Genistein can prevent acti-
vation and proliferation of HSC by inhibiting tyrosine kinase
[29]. Genistein was shown to reduce type 1 procollagen ex-
pression in rat HSC-T6 cells and to inhibit the proliferation
of HSC cells [30]. This eﬀect of genistein was not marked
at an early stage in our study. As time passes by, inhibition
of actin expression acquires signiﬁcance. Long-term proce-
dures are needed to examine antiﬁbrotic eﬀects of genis-
tein.
In conclusion, genistein can have a protective eﬀect on
liver damage from various aspects. It can prevent lipid per-
oxidation by interfering with the free radicals. It can also
strengthen the antioxidant system. Furthermore, it can pro-
vide eﬀective protection against liver damage through its
anti-inﬂammatory eﬀects.
LIST OF ABBREVIATION
DMSO:Dimetyl suphoxide
PGE: Preparation of genistein
NO: nitric oxide
LPS: lipopolysaccaride.
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